Ropes & Gray, Hogan Lovells, and Shearman & Sterling have taken the lead roles on a $5.1 billion deal in which London-based GlaxoSmithKline (GSK) will acquire Waltham, Massachusetts-based biopharmaceutical firm TESARO, Inc.
The deal is expected to strengthen GSK’s presence in cancer treatment and the treatment of tumors—an area in which TESARO is a pioneer. One of TESARO’s trademark products is the drug Zejula, which is approved for use in the U.S. and Europe and has revolutionized the treatment of ovarian cancer.
